204 related articles for article (PubMed ID: 16415903)
1. Differential activation of G-proteins by mu-opioid receptor agonists.
Saidak Z; Blake-Palmer K; Hay DL; Northup JK; Glass M
Br J Pharmacol; 2006 Mar; 147(6):671-80. PubMed ID: 16415903
[TBL] [Abstract][Full Text] [Related]
2. Biased μ-opioid receptor agonists diversely regulate lateral mobility and functional coupling of the receptor to its cognate G proteins.
Melkes B; Hejnova L; Novotny J
Naunyn Schmiedebergs Arch Pharmacol; 2016 Dec; 389(12):1289-1300. PubMed ID: 27600870
[TBL] [Abstract][Full Text] [Related]
3. Chronic exposure to mu-opioid agonists produces constitutive activation of mu-opioid receptors in direct proportion to the efficacy of the agonist used for pretreatment.
Liu JG; Prather PL
Mol Pharmacol; 2001 Jul; 60(1):53-62. PubMed ID: 11408600
[TBL] [Abstract][Full Text] [Related]
4. Opioid and cannabinoid receptors share a common pool of GTP-binding proteins in cotransfected cells, but not in cells which endogenously coexpress the receptors.
Shapira M; Vogel Z; Sarne Y
Cell Mol Neurobiol; 2000 Jun; 20(3):291-304. PubMed ID: 10789829
[TBL] [Abstract][Full Text] [Related]
5. Coupling efficacy and selectivity of the human mu-opioid receptor expressed as receptor-Galpha fusion proteins in Escherichia coli.
Stanasila L; Lim WK; Neubig RR; Pattus F
J Neurochem; 2000 Sep; 75(3):1190-9. PubMed ID: 10936202
[TBL] [Abstract][Full Text] [Related]
6. Absence of G-protein activation by mu-opioid receptor agonists in the spinal cord of mu-opioid receptor knockout mice.
Narita M; Mizoguchi H; Narita M; Sora I; Uhl GR; Tseng LF
Br J Pharmacol; 1999 Jan; 126(2):451-6. PubMed ID: 10077238
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of opioid agonists on G protein expression in CHO cells expressing cloned human opioid receptors.
Xu H; Wang X; Partilla JS; Bishop-Mathis K; Benaderet TS; Dersch CM; Simpson DS; Prisinzano TE; Rothman RB
Brain Res Bull; 2008 Sep; 77(1):49-54. PubMed ID: 18639745
[TBL] [Abstract][Full Text] [Related]
8. Gi/o-coupled receptors compete for signaling to adenylyl cyclase in SH-SY5Y cells and reduce opioid-mediated cAMP overshoot.
Levitt ES; Purington LC; Traynor JR
Mol Pharmacol; 2011 Mar; 79(3):461-71. PubMed ID: 21098043
[TBL] [Abstract][Full Text] [Related]
9. G protein activation by endomorphins in the mouse periaqueductal gray matter.
Narita M; Mizoguchi H; Narita M; Dun NJ; Hwang BH; Endoh T; Suzuki T; Nagase H; Suzuki T; Tseng LF
J Biomed Sci; 2000; 7(3):221-5. PubMed ID: 10810240
[TBL] [Abstract][Full Text] [Related]
10. Modulation by mu-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells.
Traynor JR; Nahorski SR
Mol Pharmacol; 1995 Apr; 47(4):848-54. PubMed ID: 7723747
[TBL] [Abstract][Full Text] [Related]
11. mu-Opioid receptor-stimulated guanosine-5'-O-(gamma-thio)-triphosphate binding in rat thalamus and cultured cell lines: signal transduction mechanisms underlying agonist efficacy.
Selley DE; Sim LJ; Xiao R; Liu Q; Childers SR
Mol Pharmacol; 1997 Jan; 51(1):87-96. PubMed ID: 9016350
[TBL] [Abstract][Full Text] [Related]
12. The spinal antinociceptive effects of endomorphins in rats: behavioral and G protein functional studies.
Xie H; Woods JH; Traynor JR; Ko MC
Anesth Analg; 2008 Jun; 106(6):1873-81. PubMed ID: 18499626
[TBL] [Abstract][Full Text] [Related]
13. Mu opioid receptor activation enhances regulator of G protein signaling 4 association with the mu opioid receptor/G protein complex in a GTP-dependent manner.
Santhappan R; Crowder AT; Gouty S; Cox BM; Côté TE
J Neurochem; 2015 Oct; 135(1):76-87. PubMed ID: 26119705
[TBL] [Abstract][Full Text] [Related]
14. Lack of mu-opioid receptor-mediated G-protein activation in the spinal cord of mice lacking Exon 1 or Exons 2 and 3 of the MOR-1 gene.
Mizoguchi H; Wu HE; Narita M; Sora I; Hall SF; Uhl GR; Loh HH; Nagase H; Tseng LF
J Pharmacol Sci; 2003 Dec; 93(4):423-9. PubMed ID: 14737012
[TBL] [Abstract][Full Text] [Related]
15. Specific G protein activation and mu-opioid receptor internalization caused by morphine, DAMGO and endomorphin I.
Burford NT; Tolbert LM; Sadee W
Eur J Pharmacol; 1998 Jan; 342(1):123-6. PubMed ID: 9544801
[TBL] [Abstract][Full Text] [Related]
16. Agonist-dependent mu-opioid receptor signaling can lead to heterologous desensitization.
Chu J; Zheng H; Zhang Y; Loh HH; Law PY
Cell Signal; 2010 Apr; 22(4):684-96. PubMed ID: 20043990
[TBL] [Abstract][Full Text] [Related]
17. Mu and Delta opioid receptors activate the same G proteins in human neuroblastoma SH-SY5Y cells.
Alt A; Clark MJ; Woods JH; Traynor JR
Br J Pharmacol; 2002 Jan; 135(1):217-25. PubMed ID: 11786497
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylation of the mu-opioid receptor at tyrosine 166 (Tyr3.51) in the DRY motif reduces agonist efficacy.
Clayton CC; Bruchas MR; Lee ML; Chavkin C
Mol Pharmacol; 2010 Mar; 77(3):339-47. PubMed ID: 19959593
[TBL] [Abstract][Full Text] [Related]
19. Modulation by neuropeptide FF of the interaction of mu-opioid (MOP) receptor with G-proteins.
Kersanté F; Moulédous L; Zajac JM; Mollereau C
Neurochem Int; 2010; 56(6-7):768-73. PubMed ID: 20211672
[TBL] [Abstract][Full Text] [Related]
20. Low dose combination of morphine and delta9-tetrahydrocannabinol circumvents antinociceptive tolerance and apparent desensitization of receptors.
Smith PA; Selley DE; Sim-Selley LJ; Welch SP
Eur J Pharmacol; 2007 Oct; 571(2-3):129-37. PubMed ID: 17603035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
